International Biotechnology Trust (IBT) is a leading asset management business based in the UK. It opened the day at 831.825p after a previous close of 836p. During the day the price has varied from a low of 831.825p to a high of 850p. The latest price was 840p (25 minute delay). International Biotechnology Trust is listed on the London Stock Exchange (LSE). All prices are listed in pence sterling.
Since the stock market crash in March caused by coronavirus, International Biotechnology Trust's share price has had significant positive movement.
Its last market close was 818p, which is 22.74% up on its pre-crash value of 632p and 81.37% up on the lowest point reached during the March crash when the shares fell as low as 451p.
If you had bought £1,000 worth of International Biotechnology Trust shares at the start of February 2020, those shares would have been worth £829.97 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth £1,377.10.
|52-week range||436.6947p - 852p|
|50-day moving average||825.0309p|
|200-day moving average||784.8384p|
|Dividend yield||0.25p (2.98%)|
|Earnings per share (TTM)||138.9p|
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
|1 week (2021-01-08)||0.24%|
|1 month (2020-12-16)||1.20%|
|3 months (2020-10-16)||0.72%|
|6 months (2020-07-16)||5.66%|
|1 year (2020-01-16)||35.48%|
|2 years (2019-01-16)||40.00%|
|3 years (2018-01-16)||38.61%|
|5 years (2016-01-15)||87.50%|
Valuing International Biotechnology Trust stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of International Biotechnology Trust's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
International Biotechnology Trust's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 6x. In other words, International Biotechnology Trust shares trade at around 6x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
|Revenue TTM||£55.3 million|
|Operating margin TTM||94.26%|
|Gross profit TTM||£55.3 million|
|Return on assets TTM||11.98%|
|Return on equity TTM||0%|
|Market capitalisation||£338.8 million|
TTM: trailing 12 months
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like International Biotechnology Trust.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Total ESG risk: 35.45
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and International Biotechnology Trust's overall score of 35.45 (as at 01/01/2019) is excellent – landing it in it in the 8th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like International Biotechnology Trust is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Environmental score: 8/100
International Biotechnology Trust's environmental score of 8 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that International Biotechnology Trust is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Social score: 8/100
International Biotechnology Trust's social score of 8 puts it squarely in the 8th percentile of companies rated in the same sector. This could suggest that International Biotechnology Trust is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Governance score: 8/100
International Biotechnology Trust's governance score puts it squarely in the 8th percentile of companies rated in the same sector. That could suggest that International Biotechnology Trust is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
|Total ESG score||35.45|
|Total ESG percentile||8|
|Environmental score percentile||8|
|Social score percentile||8|
|Governance score percentile||8|
Dividend payout ratio: 1913.67% of net profits
Recently International Biotechnology Trust has paid out, on average, around 1913.67% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 2.98% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), International Biotechnology Trust shareholders could enjoy a 2.98% return on their shares, in the form of dividend payments. In International Biotechnology Trust's case, that would currently equate to about 0.25p per share.
International Biotechnology Trust's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 16 July 2020 (the "ex-dividend date").
Over the last 12 months, International Biotechnology Trust's shares have ranged in value from as little as 436.6947p up to 852p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while International Biotechnology Trust's is 0.5089. This would suggest that International Biotechnology Trust's shares are less volatile than average (for this exchange).
International Biotechnology Trust plc specializes in investments in development stage and late stage companies. The majority of the fund's assets are generally invested in smaller and mid-capitalization quoted companies, with a minority in larger capitalization quoted companies. It makes long only investments. It prefers to invest in quoted or unquoted biotechnology and life sciences companies focused on drug discovery and development and in related sectors such as microbiology, life sciences, pharmaceutical research and development, gene research and development, medical devices or healthcare services. The fund seeks to invest in companies engaged in development and/or commercialization of a product, device or enabling technology and also invests in the therapeutic sub-sector. The fund also prefers to invest in companies with strong growth potential from the development and/or commercialization of either a biotechnology drug candidate, medical device or other enabling technology for medical research. It may also invest in specialty pharmaceuticals and life science tools. These companies can range from small private companies with strong science and people that need development funding, to large, multi-billion dollar biotechnology and medical device companies which have portfolios of products, many of which are already used in hospitals, clinics and pharmacies around the world. It makes majority of its investments in smaller and mid-capitalization quoted companies and seeks to invest up to thirty percent of the Company's assets in unquoted companies, while allowing an exposure of up to forty percent in unquoted companies (at the time of investment and after allowing for valuation write-ups and further follow-on investments). The fund typically invests in the United States, but seeks the best investments worldwide and so may also invest in Western Europe, Australia, and Asia. It typically invests between $1 million and $4 million in its portfolio companies. It exits its unquoted investments through the sale of the
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.